The latest progress in research on triple negative breast cancer (TNBC): Risk factors, possible therapeutic targets and prognostic markers

Journal of Thoracic Disease

Volumn 6, Issue 9, 2014, Pages 1329-1335

  Jiao, Qingli ^a   Wu, Aiguo ^a   Shao, Guoli ^a   Peng, Haoyu ^b   Wang, Mengchuan ^a   Ji, Shufeng ^a   Liu, Peng ^c   Zhang, Jian ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Prognostic marker; Risk factor; Therapeutic target; Triple negative breast cancer (TNBC)

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANDROGEN RECEPTOR; BRCA1 PROTEIN; CARBOPLATIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; GAMMA SYNUCLEIN; LACTATE DEHYDROGENASE B; LYSYL OXIDASE LIKE 2 PROTEIN; MICRORNA; MICRORNA 10B; MICRORNA 122A; MICRORNA 145; MICRORNA 205; MICRORNA 21; MICRORNA 210; MICRORNA 221; MICRORNA 222; MUCIN 1; OXIDOREDUCTASE; PROGESTERONE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

CANCER PROGNOSIS; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; GENE EXPRESSION ASSAY; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; IMMUNOMODULATION; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTIPARA; PHASE 2 CLINICAL TRIAL (TOPIC); PREMENOPAUSE; PREVALENCE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RNA ANALYSIS; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

EID: 84907698450     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2014.08.13     Document Type: Review

References (66)

1. Bosch A, Eroles P, Zaragoza R, et al. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010;36:206-15.
2. Knight JF, Lesurf R, Zhao H, et al. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc Natl Acad Sci U S A 2013;110:E1301-10.
3. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
4. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
5. Falck AK, Bendahl PO, Chebil G, et al. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up. Breast Cancer Res Treat 2013;140:93-104.
6. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 2011;117:3658-69.
7. Russo AL, Arvold ND, Niemierko A, et al. Margin status and the risk of local recurrence in patients with earlystage breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat 2013;140:353-61.
8. Schneider BP, Winer EP, Foulkes WD, et al. Triplenegative breast cancer: risk factors to potential targets. Clin Cancer Res 2008;14:8010-8.
9. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.
10. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
11. Bae YH, Ryu JH, Park HJ, et al. Mutant p53-Notch1 Signaling Axis Is Involved in Curcumin-Induced Apoptosis of Breast Cancer Cells. Korean J Physiol Pharmacol 2013;17:291-7.
12. Xu Y, Diao L, Chen Y, et al. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. Ann Oncol 2013;24:1498-505.
13. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011;16 Suppl 1:1-11.
14. Jerónimo C, Costa I, Martins MC, et al. Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res 2003;9:3413-7.
15. Zhou L, Li K, Luo Y, et al. Novel prognostic markers for patients with triple-negative breast cancer. Hum Pathol 2013;44:2180-7.
16. Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer--current status and future directions. Ann Oncol 2009;20:1913-27.
17. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control 2010;17:173-6.
18. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
19. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a populationbased study from the California cancer Registry. Cancer 2007;109:1721-8.
20. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a populationbased study in Atlanta, GA. Breast Cancer Res Treat 2009;113:357-70.
21. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-39.
22. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a singleinstitution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007;110:876-84.
23. Stead LA, Lash TL, Sobieraj JE, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 2009;11:R18.
24. Lund MJ, Butler EN, Hair BY, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer 2010;116:2549-59.
25. Al-Tamimi DM, Bernard PS, Shawarby MA, et al. Distribution of molecular breast cancer subtypes in middle eastern-saudi arabian women: a pilot study. Ultrastruct Pathol 2009;33:141-50.
26. Lin Y, Yin W, Yan T, et al. Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. BMC Cancer 2009;9:342.
27. Lin C, Chien SY, Chen LS, et al. Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer 2009;9:192.
28. Kurebayashi J, Moriya T, Ishida T, et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 2007;16 Suppl 2:S72-7.
29. Yang XR, Pfeiffer RM, Garcia-Closas M, et al. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Cancer Res 2007;67:10608-17.
30. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007;16:439-43.
31. Purrington KS, Slager S, Eccles D, et al. Genomewide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis 2014;35:1012-9.
32. Ghiasvand R, Bahmanyar S, Zendehdel K, et al. Postmenopausal breast cancer in Iran; risk factors and their population attributable fractions. BMC Cancer 2012;12:414.
33. Cheraghi Z, Poorolajal J, Hashem T, et al. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS One 2012;7:e51446.
34. Montazeri A, Sadighi J, Farzadi F, et al. Weight, height, body mass index and risk of breast cancer in postmenopausal women: a case-control study. BMC Cancer 2008;8:278.
35. Spark LC, Reeves MM, Fjeldsoe BS, et al. Physical activity and/or dietary interventions in breast cancer survivors: a systematic review of the maintenance of outcomes. J Cancer Surviv 2013;7:74-82.
36. McKenzie F, Ellison-Loschmann L, Jeffreys M, et al. Cigarette smoking and risk of breast cancer in a New Zealand multi-ethnic case-control study. PLoS One 2013;8:e63132.
37. Piva R, Spandidos DA, Gambari R. From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review). Int J Oncol 2013;43:985-94.
38. Radojicic J, Zaravinos A, Vrekoussis T, et al. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011;10:507-17.
39. Zhao R, Wu J, Jia W, et al. Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie 2011;34:675-80.
40. Maire V, Baldeyron C, Richardson M, et al. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS One 2013;8:e63712.
41. Daniel J, Coulter J, Woo JH, et al. High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. Proc Natl Acad Sci U S A 2011;108:5384-9.
42. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
43. Robinson TJ, Liu JC, Vizeacoumar F, et al. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS One 2013;8:e78641.
44. Bitler BG, Goverdhan A, Schroeder JA. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci 2010;123:1716-23.
45. Pochampalli MR, El Bejjani RM, Schroeder JA. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 2007;26:1693-701.
46. Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005;54:254-64.
47. Siroy A, Abdul-Karim FW, Miedler J, et al. MUC1 is expressed at high frequency in early-stage basal-like triplenegative breast cancer. Hum Pathol 2013;44:2159-66.
48. Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013;14:933-42.
49. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012;366:310-20.
50. Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001;61:5407-14.
51. McNamara KM, Yoda T, Takagi K, et al. Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol 2013;133:66-76.
52. Birrell SN, Roder DM, Horsfall DJ, et al. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J Clin Oncol 1995;13:1572-7.
53. Xiangying M, Shikai W, Zefei J, et al. Progestin as an alternative treatment option for multi-treated recurrent triple-negative breast cancer. Swiss Med Wkly 2013;143:w13765.
54. Engel JB, Honig A, Kapp M, et al. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. Arch Gynecol Obstet 2014;289:141-7.
55. Mahmoud SM, Paish EC, Powe DG, et al. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 2011;127:99-108.
56. Hers I, Vincent EE, Tavaré JM. Akt signalling in health and disease. Cell Signal 2011;23:1515-27.
57. López-Knowles E, O'Toole SA, McNeil CM, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010;126:1121-31.
58. Shvartsman SY, Coppey M, Berezhkovskii AM. MAPK signaling in equations and embryos. Fly (Austin) 2009;3:62-7.
59. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006;12:7242-51.
60. Park S, Jung HH, Park YH, et al. ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression. Biochem Biophys Res Commun 2011;407:680-6.
61. Singh J, Novik Y, Stein S, et al. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res 2014;16:R32.
62. Ahn SG, Dong SM, Oshima A, et al. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. Breast Cancer Res Treat 2013;141:89-99.
63. Moreno-Bueno G, Salvador F, Martín A, et al. Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Mol Med 2011;3:528-44.
64. Wu K, Huang S, Zhu M, et al. Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer. Med Oncol 2013;30:612.
65. McCleland ML, Adler AS, Shang Y, Hunsaker T, et al. An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res 2012;72:5812-23.
66. Dennison JB, Molina JR, Mitra S, et al. Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2013;19:3703-13.